Work

S1455 Real-World Comparative Effectiveness of Vedolizumab vs Upadacitinib and Risankizumab for Crohn’s Disease Through 52 Weeks

Year: 2025

Type: conference-abstract

Source: The American Journal of Gastroenterology

DOI: 10.14309/01.ajg.0001133280.73131.1b

Authors: Rahul S. Dalal, Grace Hardwick, Lindsay Clarke, Heidy Cabral, Alexander Carlin, Jessica R. Allegretti

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417163446

Cites:

Cited by:

Related to: